[{"indications": "Indications\u00a0see under Dose", "name": "FAMOTIDINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.3 Antisecretory drugs and mucosal protectants", "1.3.1 H2-receptor antagonists", "FAMOTIDINE"], "cautions": "Cautions\u00a0\n(From 1.3.1 H2-receptor antagonists: British National Formulary)\nCautions\u00a0H2-receptor antagonists might mask symptoms of gastric cancer; particular care is required in patients presenting with \u2018alarm features\u2019 (see Dyspepsia), in such cases gastric malignancy should be ruled out before treatment.; interactions: Appendix 1 (histamine H2-antagonists)\r\nand notes above", "side-effects": "Side-effects\u00a0see notes above; also constipation; less\r\ncommonly dry mouth, nausea, vomiting, flatulence, taste disorders,\r\nanorexia, fatigue; very rarely chest tightness, interstitial\r\npneumonia, seizures, paraesthesia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106212.htm", "doses": ["Benign gastric and duodenal ulceration, treatment, 40\u00a0mg\r\nat night for 4\u20138 weeks; maintenance (duodenal ulceration), 20\u00a0mg at\r\nnight", "Reflux oesophagitis, 20\u201340\u00a0mg twice daily for 6\u201312\u00a0weeks; maintenance,\r\n20\u00a0mg twice daily", "child not recommended"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid unless potential benefit\r\noutweighs risk"}]